Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
CA 2434736 A1 · Owner: University Of North Carolina At Chapel Hill · Inventors: Mailman, Richard Bernard; Huang, Xuemei; Nichols, David Earl
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the treatment of dopamine-related dysfunction using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period". The D1 agonist concentration is reduced during the "off-period" to obtain a plasma concentration of agonist that suboptimally activates D1 dopamine receptors for a period of time to prevent induction of tolerance. Specifically the method comprises the steps , of administering to a patient a full D1 agonist with a half-life of up to about 6 hours periodically at a dose resulting in a first plasma concentration of agonist capable of activating D1 dopamine receptors to produce a therapeutic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 16, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 16, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 16, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.